Clovis Oncology Inc:
- Acquires EOS (Ethical Oncology Science) S.P.A. to gain rights to Lucitanib, a unique dual-selective phase II FGFR/VEGFR inhibitor
- Says buying eos for up-front payment of $200 million, which includes $190 million in Clovis common stock and $10 million in cash
- Says will pay an additional $65 million in cash upon initial approval of Lucitanib by U.S. food and drug association
- Says co and Servier will collaborate on development of lucitanib pursuant to
Join the Conversation